Actinium Pharmaceuticals, Inc.
ATNM Healthcare Biotechnology
Actinium Pharmaceuticals, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $90,000.00, up 11.1% from fiscal 2023. In the quarter to June 2026, revenue grew 77,677.8%, EPS grew 504.6% and free cash flow fell 4.91%, each against the same quarter a year earlier.
Follow ATNM
Actinium Pharmaceuticals, Inc. (ATNM) EV/Sales
As of 16 October 2026, Actinium Pharmaceuticals, Inc. (ATNM) trades at a EV/Sales of 0.0×. Over the past ten years it has ranged from −95.1× (March 2026) to 238× (November 2022); the current reading is higher than 18% of that period. That is below the Biotechnology industry median of 9.2× and below the Healthcare sector median of 3.4×.
EV/Sales, daily
Embed this chart
Annual newest first
| Period | EV/Sales | Change |
|---|---|---|
| FY2025 | −30.9× | — |
| FY2023 | 63.0× | (51.83%) |
| FY2022 | 131× | 229.86% |
| FY2021 | 39.6× | — |
Quarterly newest first
| Period | EV/Sales | Change |
|---|---|---|
| Jun 2026 | −0.2× | — |
| Sep 2025 | −19.3× | — |
| Dec 2022 | 131× | 87.31% |
| Sep 2022 | 69.8× | — |
| 6 more quarters | Free account |
Against its own ten years
EV/Sales against peers
| Company | EV/Sales |
|---|---|
| MGX Metagenomi Therapeutics, Inc. compare | −4.5× |
| ATNM Actinium Pharmaceuticals, Inc. | 0.0× |
| BCTX BRIACELL THERAP compare | n/m |
| GRDX GridAI Technologies Corp. compare | n/m |
| GNTA Genenta Science S.p.A. Unsponsored ADR compare | n/m |
| IRLA Quince Therapeutics, Inc. compare | n/m |
| LIANY LianBio Sponsored ADR compare | n/m |
| ALGS Aligos Therapeutics, Inc. compare | 0.6× |
| CRVO CervoMed Inc. compare | 2.7× |
| Biotechnology industry median | 9.2× |
| Healthcare sector median | 3.4× |
| Market median | 2.1× |
What EV/Sales is
EV/Sales tells an investor how the value of a whole company, counting its debt and cash, compares with the sales it brings in.
((Stock Price × Shares (Basic, Weighted) (latest quarter)) + (Long Term Debt (Total) (latest quarter) + Current Part of Debt (latest quarter)) − Cash & Short Term Investments (latest quarter)) ÷ Revenue (TTM)